Becker's ASC Review

Jan_Feb_2019_ASC

Issue link: https://beckershealthcare.uberflip.com/i/1067786

Contents of this Issue

Navigation

Page 27 of 31

28 HEALTHCARE NEWS Pain physician convicted of falsifying patient medical records — 6 insights By Eric Oliver M oustafa Moataz Aboshady, MD, was found guilty of falsifying patient medical information to obtain illegal payments from Medicare and commercial insurers, according to the U.S. Attorney's Office for the District of Massachusetts. Here's what you should know: 1. Dr. Aboshady was convicted of one count of conspiracy to make false statements and two counts of making false statements regarding actions he committed between May 2012 and May 2013. 2. Dr. Aboshady practiced at New England Wellness & Pain Management, which operated a series of practices in Mas- sachusetts and Rhode Island under several names. 3. New England Wellness & Pain Management was oper- ated by Fathallah Mashali, MD. Dr. Mashali pleaded guilty to 27 counts of healthcare fraud, one count of conspiracy to commit mail fraud and 16 counts of money laundering. He faces eight years in prison. 4. Dr. Mashali and Dr. Aboshady both falsified medical re- cords to receive payments from Medicare and commercial insurers for unperformed services. 5. Dr. Aboshady also fabricated urine drug test results with false test dates. Along with partners in Cairo, Egypt, urine sample test results were fabricated to make the tests ap- pear days old, instead of either weeks or months old. 6. Dr. Aboshady faces up to five years in prison, three years of supervised release, $250,000 in fines and restitution. A federal judge will sentence him at a later date. n Kaiser Permanente Colorado lays off 200 employees By Kelly Gooch K aiser Permanente Colorado, the state's largest insurer, laid off about 200 employees in Novem- ber 2018, after unveiling financial struggles, The Denver Post reported. Kaiser spokesperson Amy Whited told the Post that the layoffs aimed to "address redundancies" in administrative positions and positions unrelated to direct patient care. "We are making operational improvements to ensure we are meeting and exceeding our members' expecta- tions for quality, service and affordability," she said. "An important part of this effort is having the right people in the right jobs to best serve our members." In October, Kaiser revealed losses of $65 million in the last three years and blamed them on rising hospital prices and "unfair business practices." The insurer said it would review its operations in Colorado after an investigation by the Post found hospitals in the state increased their prices by 76 percent over eight years. A Kaiser spokesperson told the Post the insurer is offer- ing 60 days of administrative pay, as well as severance, to those affected by the layoffs. According to the publication, Kaiser has about 40,000 Medicaid members and more than 8,000 employees in Colorado. n 10 healthcare companies likely to be acquired in 2019 By Alyssa Rege W hile the healthcare industry has historically been ripe for mergers and acquisitions activity, a recent report by Morgan Stanley analysts published in October and cited by Business Insider suggests health companies' high valua- tions and the wealth of readily available funding for biotechs are limiting the activity within the sector. e report, obtained by Becker's Hospital Review, identifies 10 healthcare companies Morgan Stanley analysts predict will receive tender offers within the next 12 months. Analysts used proprietary quantitative models to issue its predictions. e models relied on a combination of cohort information and stock-level fundamental data to forecast acquisition likelihood, among other data. Here are 10 companies likely to be acquired by the end of next year along with their market cap estimate, according to Business Insider: 1. Iqiva — $26.4 billion 2. Biomarin Pharmaceutical — $17.6 billion 3. Seattle Genetics — $12.9 billion 4. DaVita — $12.4 billion 5. Universal Health Services (King of Prussia, Pa.) — $11.7 billion 6. Dexcom — $11.5 billion 7. Neurocrine Biosciences — $10.8 billion 8. Perrigo — $9.8 billion 9. Nektar erapeutics — $9.5 billion 10. Sarepta erapeutics — $9.5 billion n

Articles in this issue

Links on this page

view archives of Becker's ASC Review - Jan_Feb_2019_ASC